Jianping Li at LBS briefing 1

Jianping Li, M.D., Ph.D., professor and executive deputy director in the department of cardiology at Peking University First Hospital in China, presents findings on DR10624, a First-In-Class, FGF21 Receptor/Glucagon Receptor/GLP-1 Receptor Triple Agonist, Rapidly and Significantly Reduced Triglycerides, Atherogenic Lipids, and Liver Fat in Patients With Severe Hypertriglyceridemia: Primary Results From a Randomized Phase 2 Trial (LBS.01) at the embargoed media briefing at Scientific Sessions 2025.

Please see AHA/ASA Multimedia Materials Usage Policy.

I have read the AHA/ASA Multimedia Materials Usage Policy and agree to the terms of use

Download (462.8 kB)

This link is provided for convenience only and is not an endorsement of either the linked-to entity or any product or service.

CLOSE PROCEED